Wen Qi focuses on investing in and building global healthcare companies from Singapore. Prior to joining ClavystBio, she headed up the Singapore investments and operations for Lightstone Ventures, where she played a major role in establishing the firm’s presence in Singapore. Wen Qi evaluated new investment opportunities in the biopharmaceutical and medical device sectors, and was actively involved in venture-building portfolio companies in Singapore such as Medisix Therapeutics, Allay Therapeutics and Ligature Therapeutics. Wen Qi is an advocate for early career researcher participation in biotech entrepreneurship, and serves on advisory and grant review panels with leading institutions in Singapore. She also serves on boards of ClavystBio’s portfolio companies. Wen Qi attained her PhD in Immunology at Stanford University, and BSc in Molecular and Cellular Biology at Johns Hopkins University.